A total of 96 proteins were identified and among them leucine-rich alpha-2-glycoprotein 1 (LRG1), clusterin (CLU), thrombin (F2), heparin cofactor II (SERPIND1), alpha-2-macroglobulin (A2M), alpha-2-antiplasmin (SERPINF2), Alpha-1 antitrypsin (SERPINA1), complement factor B (CFB) and complement C3 (C3) were identified as candidate biomarkers for early diagnosis of B-ALL, as they were up-regulated in the B-ALL group compared to controls after induction therapy [75]. This evidence concerns the gene SERPINA1 and precursor B-cell acute lymphoblastic leukemia.